COVID-19 jab: EU signs contract with JNJ
Johnson & Johnson (JNJ) has inked a contract with the European Commission to supply 200 million doses of its COVID-19 vaccine to the European Union.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2126 entries already.
Entries by Thomas Gabrielczyk
Santhera ends development of idebenone
Swiss Santhera Pharmaceuticals has discontinued Phase III development of its DMD drug and will restructure its pipeline.
Nobel Prize in Physiology for HCV pioneers
The Nobel Prize in Physiology or Medicine goes to Harvey J. Alter, Michael Houghton and Charles M. Ric
Swiss Sophia Genetics to expand globally
Swiss Sophia Genetics has raised $110m, to expand marketing of its AI-driven cancer and genetic disease decision support platform globally.
EIB and EC launch circular bioeconomy fund
The European Commission (EC) and the European Investment Bank (EIB) have launched a circular bioeconomy fund with a target size of €250m.
·
Dewpoint Therapeutics raise $77m in Series B financing
A $77 Series B financing allows Dewpoint Therapeutics Inc to select a lead programme from its new drug class of molecular condensates and push proof-of-concept studies.
Kurma Partners close diagnostics fund at €50m
The only investment fund dedicated to breakthrough diagnostics, Kurma Diagnostics 2, had its first closing at €50m.
Danish Galecto Inc. secures US$64m equity financing
Danish fibrosis and cancer specialist Galecto Inc. has raised US$64m in a Series B round led by Soleus Capital.
MosaMeat NV bags US$55m financing
Maastricht-based cultured meat producer Mosa Meat NV has raised $55m in a Series B financing, bringing its funding to $63.8m.
Pureos Bioventures closes US$170m fund
Newly formed venture capitalist Pureos Bioventures has set up a US$170m fund dedicated to Swiss and European drug developers.